Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05554029
Other study ID # 15-23
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 25, 2022
Est. completion date December 20, 2022

Study information

Verified date September 2022
Source Gazi University
Contact Songul B Yentur
Phone +90 424 2370000
Email songulbaglan23@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COVID-19 is a contagious respiratory disease that is caused Severe Acute Respiratory Syndrome causing Coronavirus-2 (SARS-CoV-2). The most common symptoms are fever, cough and dyspnoea. Patients with rheumatic diseases are at higher risk of infections because of disease activity and immunosuppression. In addition, old age and having concomitant chronic disease are among risk factors for coronavirus. Therefore, national health services recommend patients to practice self-isolation and self-quarantine.


Description:

COVID-19 is a contagious respiratory disease that is caused Severe Acute Respiratory Syndrome causing Coronavirus-2 (SARS-CoV-2). It was firstly seen in December 2019 in Wuhan, China and spread rapidly all over the world. World Health Organization (WHO) was declared COVID-19 as a pandemic in March 2020. The most common symptoms are fever, cough and dyspnoea. Social isolation and staying home have been suggested to reduce the spreading rate of COVID-19 pandemic in many countries. In addition, curfew except necessity was applied in some countries and time of curfew varied by country. Therefore, pandemic caused changes in routine life for millions of people. Patients with rheumatic diseases are at higher risk of infections because of disease activity and immunosuppression. In addition, old age and having concomitant chronic disease are among risk factors for coronavirus. Therefore, national health services recommend patients to practice self-isolation and self-quarantine. However, social isolation was concluded with more increased physical inactivity and sedentary lifestyle. The aim of this study is to investigate coronaphobia in rheumatic diseases and compare with healthy people.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 20, 2022
Est. primary completion date November 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Between the ages of 18 to 65 - Have diagnosed with Romatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erthematosus or Fibromyalgia Exclusion Criteria: - Being pregnant - Diagnosed with malignancy - Had changes of medical treatment in the last 3 months - Had dysfunction that limited physical activity such as severe neurological impairment, immobility or cooperation deficits

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Coronaphobia
Coronophobia will be assessed with COVID-19-phobia scale.

Locations

Country Name City State
Turkey Songul Baglan Yentur Ankara

Sponsors (2)

Lead Sponsor Collaborator
Gazi University Firat University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Covid-19 Phobia Scale Covid-19 Phobia Scale (C19P-S) was developed by Arpaci et al. C19P-S is a self-reported questionnaire consisting of 20 items and four, i.e., psychological, psychosomatic, economic, and social, subscales. All items are rated on a 5-point scale from "strongly disagree" to "strongly agree". The total score ranges from 20 to 100 points;,the higher the score, the higher is the level of coronaphobia. 2 minutes
Secondary Hospital Anxiety and Depression Scale It consists of 14 questions that which 7 of them evaluate depression and 7 of them evaluate anxiety. Each question is scored from 0 to 3 and high scores indicate severe anxiety and depression 3 minutes
See also
  Status Clinical Trial Phase
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT04042792 - Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Completed NCT02694796 - Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy N/A
Completed NCT02269254 - Persona Versus NexGen N/A
Completed NCT02256098 - RSA RCT: ATTUNEā„¢ TKA Versus PFC Sigma TKA N/A
Completed NCT00642837 - A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets Phase 4
Active, not recruiting NCT04704544 - Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE) N/A
Completed NCT05026853 - Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice N/A
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Recruiting NCT00024479 - Natural History of Rheumatic Diseases in Minority Communities
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT04567576 - Predictive Factors for COVID-19 in Rheumatology
Completed NCT02291471 - Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers Phase 1
Completed NCT01227694 - Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis Phase 1/Phase 2
Recruiting NCT01071447 - Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment N/A
Active, not recruiting NCT05618782 - Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee Phase 2
Active, not recruiting NCT05543642 - The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) Phase 4
Active, not recruiting NCT02694185 - Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications N/A
Completed NCT04685434 - Validity and Reliability of "Shriners Hospital Upper Extremity Evaluation" in Children With Rheumatic Disease

External Links